Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageIndivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease. For more than 25 years, Indivior has led innovation in addiction medicine, developing differentiated therapeutic solutions that support long-term patient recovery, expand access to care, and drive sustainable value for patients, healthcare systems and stockholders.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q2 2026 · $300.0MThe company’s own SEC segment disclosure.
- Sublocade$238.0M79%
- Sublingual And Other$57.0M19%
- Perseris$5.0M2%
Indivior Pharmaceuticals, Inc. (INDV) reported revenue of $343M in Q2 2026 (quarter ended Jun 30, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 86% and net income of $122M (36% of revenue). For the full year FY2025, revenue was $1.24B (+4.3% year on year) and net income $210M. Its largest product in Q2 2026 was Sublocade at $238M, 79% of the disclosed total, well ahead of Sublingual And Other at 19%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #19 of 29 by Smart Score